Roivant Sciences Ltd.
Eric Venker (President & Immunovant CEO) sells ROIV shares
AI-generated summary
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 common shares for an average price of $36.59, totaling approximately $7.3M, on October 28, 2026. Following the sale, Eric Venker directly held 1,199,154 common shares. The sale was executed under a Rule 10b5-1 trading plan adopted on June 30, 2026.
Key facts
- Insider
- Eric Venker · President & Immunovant CEO
Rule 10b5-1 plan · adopted Jun 30, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | S · open-market saleFootnotes F1 | −200,000 | $36.59 | $7,318,000.00 | 1,199,154 | Direct |
Footnotes
- F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.18 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
More ROIV filings
- 144
Filed Oct 28, 2026
- 4
Filed Oct 27, 2026
- 4
Filed Oct 27, 2026
- 4
Filed Oct 27, 2026
- SC 13G/A
Filed Oct 27, 2026
- 4
Filed Oct 22, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.